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Abstract
Inflammatory diseases of the respiratory tract are commonly associated with elevated
production of nitric oxide (NO•) and increased indices of NO•-dependent oxidative stress.
Although NO• is known to have anti-microbial, anti-inflammatory and anti-oxidant properties,
various lines of evidence support the contribution of NO• to lung injury in several disease
models. On the basis of biochemical evidence, it is often presumed that such NO•-
dependent oxidations are due to the formation of the oxidant peroxynitrite, although
alternative mechanisms involving the phagocyte-derived heme proteins myeloperoxidase and
eosinophil peroxidase might be operative during conditions of inflammation. Because of the
overwhelming literature on NO• generation and activities in the respiratory tract, it would be
beyond the scope of this commentary to review this area comprehensively. Instead, it
focuses on recent evidence and concepts of the presumed contribution of NO• to
inflammatory diseases of the lung.
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ARDS = acute respiratory distress syndrome; EPO = eosinophil peroxidase; MPO = myeloperoxidase; NO• = nitric oxide; NOS = NO• synthase;
O2•– = superoxide; ONOO– = peroxynitrite; RNS = reactive nitrogen species.
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Introduction
Since its discovery as a biological messenger molecule
more than 10 years ago, the gaseous molecule nitric
oxide (NO•) is now well recognized for its involvement in
diverse biological processes, including vasodilation, bron-
chodilation, neurotransmission, tumor surveillance, antimi-
crobial defense and regulation of inflammatory-immune
processes [1–3]. In the respiratory tract, NO• is gener-
ated enzymically by three distinct isoforms of NO• syn-
thase (NOS-1, NOS-2 and NOS-3) that are present to
different extents in numerous cell types, including airway
and alveolar epithelial cells, neuronal cells, macrophages,
neutrophils, mast cells, and endothelial and smooth-
muscle cells. In contrast with the other two NOS isoforms
(NOS-1 and NOS-3), which are expressed constitutively
and activated by mediator-induced or stress-induced cell
activation, NOS-2 activity is primarily regulated transcrip-
tionally and is commonly induced by bacterial products
and pro-inflammatory cytokines. As such, inflammatory
diseases of the respiratory tract, such as asthma, acute
respiratory distress syndrome (ARDS) and bronchiecta-
sis, are commonly characterized by an increased expres-
sion of NOS-2 within respiratory epithelial and
inflammatory-immune cells, and a markedly elevated local
production of NO•, presumably as an additional host
defense mechanism against bacterial or viral infections.
The drawback of such excessive NO• production is its
accelerated metabolism to a family of potentially harmful
reactive nitrogen species (RNS), including peroxynitrite
(ONOO–) and nitrogen dioxide (NO2•), especially in the
presence of phagocyte-generated oxidants. The formation
of such RNS is thought to be the prime reason why NO•
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can in many cases contribute to the etiology of inflamma-
tory lung disease [4–6]. Despite extensive research into
both pro-inflammatory and anti-inflammatory actions of
NO•, the overall contribution of NO• to inflammatory con-
ditions of the lung is not easily predicted and seems to
depend on many factors, such as the site, time and
degree of NO• production in relation to the local redox
status, and the acute or chronic nature of the immune
response. In addition, our current understanding of the
pro-inflammatory or pro-injurious mechanisms of NO• or
related RNS is incomplete; this commentary will focus
primarily on these latter aspects.
Evidence for a pro-inflammatory role of NO• in
the respiratory tract
To explore a role for NO• (or NOS) in infectious or inflam-
matory diseases, two general research approaches have
been taken: the use of pharmacological inhibitors of NOS
isoenzymes, and the targeted deletion of individual NOS
enzymes in mice. Both approaches suffer from the short-
coming that animal models of respiratory tract diseases
generally do not faithfully reflect human disease. The use of
NOS inhibitors to determine the contribution of individual
NOS isoenzymes is also hindered by problems related to
specificity and pharmacokinetic concerns. However, the
unconditional gene disruption of one or more NOS iso-
forms, leading to lifelong deficiency, can have a markedly
different outcome from pharmacological inhibition at a
certain stage of disease, as the involvement of individual
NOS isoenzymes can be different depending on disease
stage and severity. Despite these inherent limitations,
studies with the targeted deletion of NOS isoforms have
led to some insights, indicating a role for NO• and NOS-2
in the etiology of some inflammatory lung diseases. For
instance, mice deficient in NOS-2 are less susceptible to
lethality after intranasal inoculation with influenza A virus,
suffer less lung injury after administration of endotoxin, and
display reduced allergic eosinophilia in airways and lung
injury in a model of asthma, than their wild-type counter-
parts [7–9]. However, although the contribution of NOS-2
is expected in inflammatory conditions, recent studies have
determined that NOS-1, rather than NOS-2, seems to be
primarily involved in the development of airway hyper-reac-
tivity in a similar asthma model [10]. The linkage of NOS-1
to the etiology of asthma was more recently supported in
asthmatic humans by an association of a NOS-1 gene
polymorphism with this disease, although the physiological
basis for this association remains unclear [11].
Despite the potential contribution of NOS-2-derived NO•
to lung injury after endotoxemia, the sequestration of neu-
trophils in the lung and their adhesion to postcapillary and
postsinusoidal venules after administration of endotoxin
were found to be markedly increased in NOS-2-deficient
mice, and NOS-2 deficiency did not alleviate endotoxin-
induced mortality. It therefore seems that the ‘harmful’ and
‘protective’ effects of NOS-2 might contend with each
other within the same model, which makes the assess-
ment of the potential role of NOS in human disease even
more difficult. In this context, it is interesting to note that
humans or animals with cystic fibrosis have subnormal
levels of NOS-2 in their respiratory epithelium, related to a
gene mutation in the cystic fibrosis transmembrane con-
ductance regulator [12]. This relative absence of epithelial
NOS-2 might be one of the contributing factors behind
the excessively exuberant respiratory tract inflammatory
response in patients with cystic fibrosis, even in the
absence of detectable respiratory infections. Overall, the
apparently contrasting findings associated with NOS defi-
ciency, together with concerns about animal disease
models used, make interpretations and conclusions with
regard to human lung disease all the more difficult.
Pharmacological inhibitors of NOS have also been found
to reduce oxidative injury in several animal models of lung
injury, such as ischemia/reperfusion, radiation, paraquat
toxicity, and endotoxemia (see, for example, [13–15]).
However, results are again not always consistent, and in
some cases NOS inhibition has been found to worsen
lung injury, indicating anti-inflammatory or protective roles
for NO•. All in all, despite these inconsistencies, there is
ample evidence from such studies to suggest a contribut-
ing role of NO• in various respiratory disease conditions,
which continues to stimulate research into mechanistic
aspects underlying such pro-inflammatory roles and modu-
lation of NO• generation as a potential therapeutic target.
Injurious properties of NO•: a role for ONOO–?
Although the pro-inflammatory and injurious effects of
NO• might be mediated by a number of diverse mecha-
nisms, it is commonly assumed that such actions are
largely due to the generation of reactive by-products gen-
erated during the oxidative metabolism of NO•; these are
collectively termed RNS. One of the prime suspects com-
monly implicated in the adverse or injurious properties of
NO• is ONOO–, a potent oxidative species formed by its
almost diffusion-limited reaction with superoxide (O2•–),
which is a product of activated phagocytes and of
endothelial or epithelial cells [4,5,13]. The formation of
ONOO– seems highly feasible under conditions of ele-
vated production of both NO• and O2•– in vivo, and its
oxidative and cytotoxic potential is well documented
[5,6]. However, because the direct detection of ONOO–
under inflammatory conditions is virtually impossible
because of its instability and high reactivity, the formation
of ONOO– in vivo can be demonstrated only by indirect
methods. Thus, many investigators have relied on the
analysis of characteristic oxidation products in biological
molecules, such as proteins and DNA, most notably free
or protein-associated 3-nitrotyrosine, a product of tyro-
sine oxidation that can be formed by ONOO– (and
several other RNS) but not by NO• itself (see, for
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example, [5]). Indeed, elevated levels of 3-nitrotyrosine
have been observed in many different inflammatory condi-
tions of the respiratory tract [16], which illustrates the
endogenous formation of ONOO– or related RNS in
these cases. However, without known evidence for func-
tional consequences of (protein) tyrosine nitration, the
detection of 3-nitrotyrosine should not be regarded as
direct proof of a pro-inflammatory role of NO•. Moreover,
although the detection of 3-nitrotyrosine has in most
cases been interpreted as conclusive evidence for the
formation of ONOO– in vivo (see, for example, [17]), it
should be realized that other RNS formed by alternative
mechanisms might also contribute to endogenous tyro-
sine nitration. Indeed, it has recently become clear that
the presence of inflammatory-immune cells, and specifi-
cally their heme peroxidases myeloperoxidase (MPO) and
eosinophil peroxidase (EPO), can catalyze the oxidization
of NO• and/or its metabolite NO2– to more reactive RNS
and thereby contribute to protein nitration [16,18,19].
This notion is further supported by the fact that 3-nitroty-
rosine is commonly detected in tissues affected by active
inflammation, mostly in and around these phagocytic cells
and macrophages, which can also contain active peroxi-
dases originating from apoptotic neutrophils or
eosinophils. Hence, the detection of 3-nitrotyrosine in
vivo cannot be used as direct proof of the formation of
ONOO–, but merely indicates the formation of RNS by
multiple oxidative pathways, possibly including ONOO–
but more probably involving the activity of phagocyte per-
oxidases [16,20]. In this regard, a preliminary study with
EPO-deficient mice has recently demonstrated the critical
importance of EPO in the formation of 3-nitrotyrosine in a
mouse model of asthma [21]. Future studies with animals
deficient in MPO and/or EPO will undoubtedly help to
clarify this issue.
Protein tyrosine nitration in the lung: does it
really matter?
Given the considerable interest in 3-nitrotyrosine as a col-
lective marker of the endogenous formation of NO•-
derived RNS, the crucial question remains of whether the
detection of 3-nitrotyrosine adequately reflects the toxic or
injurious properties of NO•. The formation of ONOO– (or
of other RNS that can induce tyrosine nitration) might in
fact represent a mechanism of decreasing excessive
levels of NO• that might exert pro-inflammatory actions by
other mechanisms. For instance, NO• can promote the
expression of pro-inflammatory cytokines or cyclo-oxyge-
nase (responsible for the formation of inflammatory
prostanoids) by mechanisms independent of ONOO–
[22,23], and the removal of NO• would minimize these
responses. Furthermore, although ONOO– or related NO•-
derived oxidants can be cytotoxic or induce apoptosis,
these effects might not necessarily relate to their ability to
cause protein nitration (see, for example, [16]). For
instance, the bactericidal and cytotoxic properties of
ONOO– are minimized by the presence of CO2, even
though aromatic nitration and other radical-induced modifi-
cations are enhanced [5]. Similarly, the presence of NO2–
in the incubation medium decreases the cytotoxicity of
MPO-derived hypochlorous acid (HOCl) toward epithelial
cells or bacteria, despite increased tyrosine nitration of
cellular proteins (A van der Vliet and M Syvanen, unpub-
lished data). Thus, it would seem that the cytotoxic proper-
ties of NO• and/or its metabolites might instead be
mediated through preferred reactions with other biological
targets, and these might not necessarily be correlated with
the degree of tyrosine nitration. The extent of nitrotyrosine
immunoreactivity in bronchial biopsies of asthmatic
patients was correlated directly with measured levels of
exhaled NO• and inversely with the provocation concentra-
tion for methacholine (PC20) and forced expiratory volume
in 1 s [24]. However, an immunohistochemical analysis of
nitrotyrosine and apoptosis in pulmonary tissue samples
from lung transplant recipients did not identify patients
with an imminent risk of developing obliterative bronchioli-
tis [25]. It is therefore still unclear to what degree tyrosine
nitration relates to disease progression.
Several studies with purified enzymes have suggested that
nitration of critical tyrosine residues adversely affects
enzyme activity, but there is as yet no conclusive evidence
in vivo for biological or cellular changes as a direct result of
tyrosine nitration [16,20]. For instance, tyrosine nitration
was suggested to have an effect on cellular pathways by
affecting cytoskeletal proteins or tyrosine phosphorylation,
thereby affecting processes involved in, for example, cell
proliferation or differentiation [16,26]. Recent studies have
provided support for selective tyrosine nitration within
certain proteins [27,28] and of selective cellular targets for
nitration by RNS (see, for example, [29,30]), and such
specificity might indicate a potential physiological role for
this protein modification. However, in none of these cases
could tyrosine nitration be linked directly to changes in
enzyme function. Chemical studies have indicated that tyro-
sine nitration by RNS accounts for only a minor fraction of
oxidant involved, and reactions with other biological targets
(thiols, selenoproteins, or transition metal ions) are much
more prominent [5,6]. Indeed, the extent of tyrosine nitra-
tion in vivo is very low (1–1000 per 106 tyrosine residues
according to best estimates [16]), although different analyt-
ical methods used to detect 3-nitrotyrosine in biological
systems have often given inconsistent results. It is impor-
tant to note that recent rigorous studies have unveiled sub-
stantial sources of artifact during sample preparation,
which might frequently have led to an overestimation of
tyrosine nitration in vivo in previous studies [31].
On the basis of current knowledge, the formation of
3-nitrotyrosine seems to be merely a marker of NO•-
derived oxidants, with as yet questionable pathophysiolog-
ical significance. In view of the low efficiency of tyrosine
nitration by biological RNS, and the endogenous presence
of variable factors that influence protein nitration (antioxi-
dants or other RNS scavengers), it seems unlikely that
tyrosine nitration is a reliable mechanism of, for example,
enzyme regulation. Nevertheless, the recent discovery of
enzymic ‘denitration’ mechanisms that can reverse tyro-
sine nitration [32] merits further investigation of the possi-
bility that tyrosine nitration might reflect a signaling
pathway, for example analogous to tyrosine phosphoryla-
tion or sulfation.
Direct and indirect signaling properties of NO•
The biological effects of NO• are mediated by various
actions, either by NO• itself or by secondary RNS, and
the overall biochemistry of NO• is deceptively complex.
Moreover, the metabolism and chemistry of NO• depend
importantly on local concentrations and pH; the recently
described acidification of the airway surface in asthmat-
ics [33] might significantly affect NO• metabolism in
these patients. It is well known that interactions with the
ion centers of iron or other transition metals are responsi-
ble for many of the signaling properties of NO•; the acti-
vation of the heme enzyme guanylyl cyclase and the
consequent formation of cGMP is involved not only in
smooth-muscle relaxation but also in the activation of
certain transcription factors, the expression of several
pro-inflammatory and anti-inflammatory genes (including
cytokines and cyclo-oxygenase), and the production of
respiratory mucus [22–34]. In addition to such direct sig-
naling properties, many actions of NO• might be due
largely to secondary RNS that can react with multiple
additional targets, in some cases forming nitroso or nitro
adducts as potentially unique NO•-mediated signaling
mechanisms. As discussed, the formation of protein
nitrotyrosine has been postulated as a potential RNS-
specific signaling pathway. Even more interest has been
given to the reversible S-nitros(yl)ation of protein cys-
teine residues, which has been proposed to affect a
number of redox-sensitive signaling pathways, for
example by the activation of p21ras or the inhibition of
protein tyrosine phosphatases [35,36]. Similar modifica-
tions of reactive cysteine residues in transcription factors
such as nuclear factor-κB or of caspases contribute to
the regulation of gene expression and apoptosis
[37–39]. The precise mechanisms leading to protein
S-nitrosylation in vivo are still not clarified, but might
involve dinitrogen trioxide (formed during the autoxidation
of NO•), iron-nitrosyl complexes, and perhaps ONOO–
[16]; changes in NO• metabolism during inflammatory
lung diseases undoubtedly affect such NO•-dependent
signaling pathways. In addition, S-nitrosylation can be
reversed by either enzymic (thioredoxin or glutaredoxin)
or chemical (metals or oxidants) mechanisms, and evi-
dence is increasing that this reversible modification is
complementary to more widely accepted oxidant-dependent
redox signaling pathways [40]. The reported alterations in
S-nitrosothiol levels in tracheal secretions of patients
with asthma or cystic fibrosis further point to altered NO•
metabolism in these cases, and might provide new clues
to the role of S-nitrosylation in controlling such disease
processes [41,42]. Unfortunately, technical limitations to
detect S-nitrosylation in specific protein targets in vivo
have limited a full understanding of this potential signal-
ing pathway; further research in these areas can be
expected to establish more clearly its significance in the
pathophysiological properties of NO•.
What is to come?
Despite the by now overwhelming evidence for the
increased formation of NO• and NO•-derived oxidants in
many different lung diseases, the exact contribution of
NO• or its metabolites to inflammatory lung disease is still
unclear. Indeed, NO• might have distinctly different roles in
different stages of respiratory tract inflammatory diseases,
being pro-inflammatory or pro-injurious in acute and
severe stages but perhaps being protective and anti-
inflammatory in more stable conditions; it is uncertain
whether NOS is a suitable therapeutic target in the man-
agement of inflammatory lung disease. Caution is clearly
needed when interpreting observations of tyrosine nitra-
tion in animal models of disease or in human tissues,
which does not automatically implicate ONOO– (as often
thought), but rather indicates the formation of RNS by
various mechanisms. Furthermore, animal models of
chronic lung disease that usually reflect short-term or
acute inflammation might not always be applicable to
chronic airway diseases in humans. For instance, phago-
cyte degranulation, a common feature observed in associ-
ation with human airway inflammatory diseases such as
asthma, does not seem to occur in mouse models of
asthma [43]. Therefore the importance of granule proteins,
such as heme peroxidases, in the pathology of human
airway diseases might not be adequately reflected in such
animal models. More work with animal models more char-
acteristic of human diseases or with biopsy materials from
human subjects will be required to unravel the precise role
of NO• in inflammatory lung disease, and might establish
more clearly whether the pharmacological inhibition of
NOS isoenzymes can be beneficial. This brings up the
interesting paradox that, despite presumed adverse roles
of NO• in such inflammatory lung diseases as septic shock
and ARDS, NO• inhalation has been suggested as a
potential therapeutic strategy to improve overall gas
exchange [44]. Intriguingly, in a rat model of endotoxemia,
inhalation of NO• was found to reduce neutrophilic inflam-
mation and protein nitration [45], again supporting the
crucial involvement of inflammatory-immune cells in this
protein modification.
For a better assessment of the role of NO• in respiratory
tract diseases in humans, the production of RNS and/or
characteristic markers would need to be more carefully
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monitored during various disease stages. Care should be
given to analytical techniques, their quantitative capacity
and the possibility of artifacts. The monitoring of exhaled
NO•, although convenient and non-invasive, does not
reflect the actual production or fate of NO• in the respira-
tory tract and is not well correlated with NOS activity in
the lung [46]. We therefore need to continue research into
the local biochemistry of NO• in the lung, taking into
account the presence of secreted or phagocyte peroxi-
dases and possible changes in local pH, as in asthmatic
airways [33], that might modulate NO• activity and metab-
olism. This might result in a better understanding of rela-
tionships between the various metabolic endproducts of
NO• (NO2–, NO3–, or nitroso and nitro adducts) and its
pro-inflammatory or injurious properties.
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